Title :

Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT.

Author(s) :

Nagler, A. [Auteur]
Ngoya, Maud [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Galimard, Jacques-Emmanuel [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Labopin, Myriam [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Kröger, N. [Auteur]
Socié, Gerard [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Gedde-Dahl, T. [Auteur]
Potter, V. [Auteur]
Schroeder, T. [Auteur]
Platzbecker, U. [Auteur]
Ganser, A. [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Salmenniemi, U. [Auteur]
Maertens, J. [Auteur]
Craddock, C. [Auteur]
Labussière-Wallet, Hélène [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Savani, B. [Auteur]
Mohty, Mohamad [Auteur]
Centre de Recherche Saint-Antoine [CRSA]

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant

Volume number :

57

Pages :

1788–1796

Publication date :

2022-09-20

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000–2010 and ...
Show more >Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000–2010 and 2887 in 2011–2020. Median age was 54 (range, 18–74) and 59 (range, 18–78) years, respectively (p < 0.0001). Donors were MSD in 65% vs. 37%, 10/10 UD in 27% vs. 50%, and 9/10 UD in 8% vs. 13%, respectively (p < 0.0001). Conditioning was myeloablative in 46% and 38%, respectively. Two-year non-relapse mortality (NRM) was lower in patients transplanted in 2011–2020 vs. those transplanted in 2000–2010, 18% vs. 21% (hazard ratio (HR) = 0.82, 95% CI: 0.68–0.9; p = 0.04) and modified GVHD-free, relapse-free survival (GRFS) (HR = 0.9, 95% CI: 0.81–0.99; p = 0.04) was better in patients transplanted in the 2011–2020 vs. those transplanted in 2000–2010. Two-year relapse incidence (RI) was similar between the 2 groups with 32% vs. 31%, (HR = 1.05, 95% CI: 0.9–1.22; p = 0.55). Likewise, leukemia-free survival (LFS) (HR = 0.95, 95% CI: 0.84–1.07; p = 0.38) and overall survival (OS) (HR = 0.93, 95% CI: 0.82–1.05; p = 0.26) were not significantly different between the two periods. In conclusion, Incidence of NRM has been significantly reduced and GRFS significantly increased in HSCT for sAML in the last 2 decades.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T00:35:50Z
2024-03-11T13:51:58Z